Drug detection test kit RIDASCREEN®

clinicalserumplasma

RIDASCREEN® Anti-IFX Antibodies is an enzyme linked immunoassay intended for the quantitative determination of antibodies to infliximab (ATI) in human serum and plasma. Key features CE-marked versions of the ELISA tests of KU Leuven Highly specific antibodies Validated in clinical trials Validated on automated ELISA readers (e.g. DSX®) Therapeutic Drug Monitoring Infliximab (IFX) is a chimeric antibody that targets the pro-inflammatory cytokine TNF-alpha. The introduction of infliximab has revolutionized the treatment of chronic inflammatory diseases like inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthritis. It has been shown that infliximab can induce deep remission and improve the patient’s quality of life. Some patients do not respond to infliximab therapy upon induction (primary non-responders), while others lose response over time (secondary non-responders). Immunogenicity Secondary loss of response is often due to the development of anti-infliximab antibodies (ATI), because of the immunogenic character of the drug. ATI can develop in any patient undergoing infliximab therapy and are primarily neutralizing the activity of infliximab through immunocomplex formation. In addition, these immunocomplexes are rapidly cleared from the system. Analytically, they are responsible for subtherapeutic infliximab concentrations. Therefore, in the case of very low trough concentrations of infliximab (< 1 μg/ml), subsequent measurement of ATI may be helpful to determine the optimal treatment strategy.